Vesicar tablets are used for the symptomatic treatment of urgency (imperative) urinary incontinence and / or frequent urination, as well as urgency (imperative) urge to urinate, characteristic of patients with overactive bladder syndrome.
The active ingredient is solifenacin succinate (one tablet contains 5 mg of solifenacin succinate).
Excipients: lactose monohydrate, corn starch, hypromellose, magnesium stearate; shell composition: opadry yellow 03F12967 (hypromellose, talc, macrogol 8000, titanium dioxide (E 171), iron oxide yellow (E172)).
The drug is contraindicated:
Adults, including elderly patients: the recommended dose is 5 mg once a day. If necessary, the dose can be increased to 10 mg once a day.
"Vesicar ™" is taken orally, the tablets are swallowed whole with a liquid, regardless of the meal.
Pregnant
There are no clinical data on women who become pregnant while using solifenacin. Animal studies have shown no direct adverse effects on fertility, embryo / fetal development, or childbirth. The potential risk is unknown. Use caution when using this drug in pregnant women.
The use of the drug "Vesicar ™" is not recommended during breastfeeding.
Children
The safety and efficacy of the drug in children has not been studied, therefore, "Vesicar ™" should not be prescribed to this category of patients.
Drivers
Due to the fact that solifenacin, like other anticholinergic drugs, can cause blurred vision and rarely drowsiness and fatigue, taking the drug can negatively affect the ability to drive a car and other mechanisms.
Symptoms
Overdose of solifenacin succinate can lead to severe anticholinergic effects. The highest dose of solifenacin succinate taken by chance by one patient was 280 mg over 5 hours, there were changes in mental state that did not require hospitalization.
Treatment
In case of an overdose of solifenacin succinate, the patient needs to take activated charcoal. Gastric lavage may be helpful if done within one hour of taking the drug, but vomiting should not be induced.
Vesicar ™ can cause side effects associated with the anticholinergic effect of solifenacin, which are generally mild to moderate. Their frequency depends on the dose of the drug. The most common side effect is dry mouth, which was observed in 11% of patients who received a dose of 5 mg per day, in 22% of patients who received a dose of 10 mg per day, in 4% who received a placebo. The severity of dry mouth, as a rule, was mild, and only in rare cases led to discontinuation of treatment. In general, the drug was reasonably well tolerated (about 99%), and approximately 90% of patients took the drug for the full study period, which lasted 12 weeks.
Store at a temperature not exceeding 25 ° C, out of the reach of children.
Shelf life is 3 years.
There are no reviews for this product.